@article{Shang2024, 
author = {Mingge Shang and Yaohui Zhang and Junjie Qian and Wenchao Wang and Xizhi Yu and Jiacheng Huang and Lin Zhou and Shusen Zheng},
title = {M2-type macrophage membrane-mediated delivery of Carvedilol nanocomplex for acute liver failure treatment and remodeling inflammatory microenvironment},
year = {2024},
journal = {Nano Research},
volume = {17},
number = {7},
pages = {6362-6375},
keywords = {acute liver failure, hepatic drug delivery, M2 macrophage-camouflaged nanoplatform, inflammatory microenvironment, macrophage polarization},
url = {https://www.sciopen.com/article/10.1007/s12274-024-6590-9},
doi = {10.1007/s12274-024-6590-9},
abstract = {Interactions of hepatic macrophages with local inflammatory microenvironment is the key factor promoting the development of acute liver failure (ALF). Hence, reprogramming pro-inflammatory M1 into anti-inflammatory M2 phenotype may offer a promising strategy for treating ALF by targeting inflammation. Our group found Carvedilol possessed potential anti-inflammatory property previously, which had been scarcely reported in ALF. We present a synergy strategy to induce macrophages into the phenotype M2-type anti-inflammatory macrophages with interleukin-4 (IL-4) and IL-10 at first. Then Carvedilol is loaded on the macrophage membrane-camouflaged biomimetic nano-platform (termed as M2M@CNP) to evade reticuloendothelial system (RES) and afford Carvedilol delivery to the inflammatory environment with overproduced reactive oxygen species (ROS), further prolonging its circulation and accumulation. Sustainably released Carvedilol produced anti-inflammatory, antioxidant and anti-apoptosis effects, combining local M2-type cell membranes (M2-CM) inhibited pro-inflammatory cytokines and ROS levels, which in turn promoted and amplified M1 to M2 phenotype polarization efficiency. This study offers new insights into the rational design of biomimetic nanosystems for safe and effective ALF therapy to accelerate the clinical translation.}
}